Who Created Tirzepatide, and Why It Matters for Your Treatment Decision

Why Lilly built a medicine with two targets instead of one

The question of who created Mounjaro is really a question about why. Eli Lilly's researchers had spent years studying GIP (glucose-dependent insulinotropic polypeptide) alongside the more familiar GLP-1. Both hormones are released from the gut after eating. Both signal the brain to reduce hunger. But until tirzepatide, no licensed weight-loss medicine activated GIP receptors at all; Lilly's scientists engineered a single molecule capable of binding to both receptor types with high affinity.

The practical consequence is a more pronounced reduction in appetite and calorie intake than single-pathway medicines typically produce. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, thousands of adults without diabetes lost an average of roughly 20–21% of their body weight over 72 weeks at the 15mg dose. That level of evidence directly informed NICE's recommendation of tirzepatide in technology appraisal TA1026, published in December 2024.

Understanding the origin of the molecule matters because it explains the titration schedule. The starting dose of 2.5mg exists to let your body adjust to both receptor pathways gradually — the first pen's job is settling your system, not producing weight loss outright. Dose increases are a clinical decision, not a personal one.

From lab to licensed medicine: Lilly's development path and the UK licence

Lilly pursued tirzepatide simultaneously for type 2 diabetes and for weight management, running the SURPASS programme (diabetes) and the SURMOUNT programme (weight loss) in parallel. The combined clinical programme involved more than 10,000 participants across both conditions. If you want a fuller account of the development timeline, the history of when tirzepatide was created covers the regulatory milestones in more detail.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines; the European Medicines Agency has no authority here post-Brexit. Mounjaro received its UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or type 2 diabetes. It carries a Black Triangle (▼) designation, meaning the MHRA collects additional safety data as real-world use grows, standard practice for newer medicines, not a concern flag.

Eli Lilly supplies Mounjaro to UK pharmacies through the licensed supply chain. The KwikPen that arrives in a plain, unbranded box via tracked DPD delivery comes from that regulated route, a point worth knowing given the volume of counterfeit tirzepatide pens the MHRA has seized from illegal sellers online.

What knowing the creator tells you about choosing treatment

The manufacturer matters in a practical sense. Lilly's relationship with authorised UK distributors is what makes it possible for a regulated pharmacy to source genuine Mounjaro. It also explains why the pen format is standardised: each KwikPen contains four weekly doses, and strengths run from 2.5mg through to 15mg in fixed steps. There is no variation in pen design between one legitimate pharmacy and another, the product is identical across the licensed supply chain.

Where providers do differ is in the clinical process around it. Suitability for tirzepatide is assessed dose by dose; a prescriber reviews your weight, health history and any medicines you already take before each supply. That review is not a formality. The foods that interact with tirzepatide and the broader question of what to eat on Mounjaro are two of the most common practical questions that come up at that stage, because the medicine slows gastric emptying and protein intake becomes especially important. Cost context is worth reading about separately, a breakdown of Mounjaro pricing in the UK explains why the list price rose sharply from September 2025 and what a legitimate private price actually covers.

The decision you are really making is not which brand to trust; Lilly is the only manufacturer. The decision is whether tirzepatide is clinically appropriate for you, at what dose, and through which service. That is precisely what a prescriber trained in weight management is there to work through with you. If you would like to start that conversation, speak to our prescribers, the initial consultation is free, and a GPhC-registered prescriber reviews every response the same day.